Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer

Authors: Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

Source: Breast Cancer Research, Vol 27, Iss 1, Pp 1-8 (2025)

Subject Terms: Trastuzumab-Deruxtecan, Pneumonitis, Breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1465-542X

Access URL: https://doaj.org/article/6c5f29284a0f4779bc15493350b692d2

The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer

Authors: Kai C. C. Johnson, Ai Ni, Dionisia Quiroga, Ashley C. Pariser, Preeti K. Sudheendra, Nicole O. Williams, Sagar D. Sardesai, Mathew Cherian, Daniel G. Stover, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, Maryam Lustberg, Sachin Jhawar, Roman Skoracki, Robert Wesolowski

Source: npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2374-4677

Access URL: https://doaj.org/article/fc9fb37c438d44728b8717088153f8ae

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Authors: Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

Source: Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/6ac20f46999d4c22ad7ae1d4db6d5b32

Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer

Authors: Jasmine S. Sukumar, Sagar Sardesai, Andy Ni, Nicole Williams, Kai Johnson, Dionisia Quiroga, Bhuvana Ramaswamy, Robert Wesolowski, Mathew Cherian, Daniel G. Stover, Margaret Gatti‐Mays, Ashley Pariser, Preeti Sudheendra, Mridula A. George, Maryam Lustberg

Source: Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)

Subject Terms: adjuvant therapy, breast cancer, endocrine therapy, HER2‐positive, hormone receptor positive, premenopausal, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/95ee2addb7d44134809b3c59d72db720

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Authors: Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

Source: Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/c4e454b0c3264101a45975daf5ec89e4

Comparing the rate of immunotherapy treatment change due to toxicity by sex

Authors: Kevin J. Chua, Shane Kronstedt, Alain Kaldany, Arnav Srivastava, Sai Krishnaraya Doppalapudi, Hao Liu, Ahmad A. Tarhini, Margaret Gatti‐Mays, Elizabeth Gaughan, Siwen Hu‐Lieskovan, Raid Aljumaily, Kenneth Nepple, Bryan Schneider, Joshua Sterling, Eric A. Singer

Source: Cancer Reports, Vol 7, Iss 2, Pp n/a-n/a (2024)

Subject Terms: cancer, drug side effects, immunotherapy, oncology, sex differences, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2573-8348

Access URL: https://doaj.org/article/e33cef4ad0604f29894c47281a57ee1a

Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls

Authors: Kai CC Johnson, Michael Grimm, Jasmine Sukumar, Patrick M. Schnell, Ko Un Park, Daniel G. Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Ashley Pariser, Preeti Sudheendra, Gary Tozbikian, Bhuvaneswari Ramaswamy, Dureti Doto, Mathew A. Cherian

Source: Breast, Vol 72, Iss , Pp 103591- (2023)

Subject Terms: Inflammatory breast cancer, Overall survival, Disease-free survival, Neoadjuvant chemotherapy, Complete pathological response, Stage 3, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977623005672; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/98353212f4f4495c9d1e8802ab738b0c

Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study

Authors: Sarah Asad, Adrienne Damicis, Yujing J. Heng, Kathryn Kananen, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi, Daniel G. Stover

Source: Breast Cancer Research, Vol 24, Iss 1, Pp 1-16 (2022)

Subject Terms: Breast cancer, Tumor microenvironment, Tumor infiltrating lymphocytes, Gene expression signature, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1465-542X

Access URL: https://doaj.org/article/bfd391b7b4c543cc8e9f6b20a3f6dcf9

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

Authors: Anne Mills, Leisha A Emens, Mary L Disis, Kunle Odunsi, John B Liao, Tyler Curiel, Margaret Gatti-Mays, Amir Jazaeri, Emese Zsiros, Marcus O Butler, Jyoti Bajpai, Katherine C Kurnit, Haider Mahdi, Laura Doherty, Claire F Friedman, Melissa A Geller, Sarah F Adams, Shelley A Dodt, Veena S John

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/11/6/e006624.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/6f1e3daea3444bceab3032c2fa552117

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Authors: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston, Jung-Min Lee

Source: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)

Subject Terms: Ovarian cancer, Immune checkpoint inhibitor, PARP inhibitor, VEGF inhibition, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s40425-019-0680-3; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/eb461ecb544343d883020500c12dca8f

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis

Authors: Margaret Gatti-Mays

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/9/2/e002252.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/7afff7a5e06c430b8ae04c23a1a9a6d2